Overview

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

Status:
COMPLETED
Trial end date:
2022-12-29
Target enrollment:
Participant gender:
Summary
The goal of the study is to learn what happens to levels of MK-0616 in the blood when MK-0616 is given in different forms. Researchers believe that there is no effect on a healthy person's body if MK-0616 is given in different forms.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC
Treatments:
MK-0616